Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Daneshmand S, Kamat AM, Shore ND, Meeks JJ, Galsky MD, Jacob JM, van der Heijden MS, Williams SB, Powles T, Chang SS, Catto JWF, Psutka SP, Guerrero-Ramos F, Xylinas E, Miyake M, Simone G, Daniel K, Sweiti H, Cutie C, Necchi A. Daneshmand S, et al. Among authors: xylinas e. Urol Oncol. 2025 Jan 15:S1078-1439(24)01044-5. doi: 10.1016/j.urolonc.2024.12.264. Online ahead of print. Urol Oncol. 2025. PMID: 39818460 Free article. Review.
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M; EuroGemDoce Study Group Collaborators; European Association of Urology ‐ Young Academic Urologists (EAU‐YAU); Urothelial Carcinoma Working Group. Scilipoti P, et al. Among authors: xylinas e. BJU Int. 2025 Jan 11. doi: 10.1111/bju.16645. Online ahead of print. BJU Int. 2025. PMID: 39797535
Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines.
Rai BP, Parmar K, Pradere B, Capoun O, Soukup V, Gontero P, Soria F, Birtle A, Compérat EM, Dominguez-Escrig JL, Yuan Y, Liedberg F, Mostafid H, Rouprêt M, Teoh JY, Moschini M, Mariappan P, van Rhijn BWG, Shariat SF, Xylinas E, Masson-Lecomte A, Seisen T. Rai BP, et al. Among authors: xylinas e. Eur Urol Oncol. 2025 Jan 7:S2588-9311(24)00292-X. doi: 10.1016/j.euo.2024.12.009. Online ahead of print. Eur Urol Oncol. 2025. PMID: 39779382 Review.
Reply to Laila Schneidewind, Fabian P. Stangl, Jennifer Kranz, and Gernot Bonkat's Letter to Editor re: Fredrik Liedberg, Evanguelos Xylinas, Paolo Gontero. Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guérin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box? Eur Urol Focus 2024;10:564-6.
Liedberg F, Xylinas E, Gontero P. Liedberg F, et al. Among authors: xylinas e. Eur Urol Focus. 2024 Dec 17:S2405-4569(24)00260-8. doi: 10.1016/j.euf.2024.12.001. Online ahead of print. Eur Urol Focus. 2024. PMID: 39694738 No abstract available.
SAFE: Multi-institutional study of time to complications after robot-assisted partial nephrectomy, selection of a population eligible for outpatient management (UroCCR 90).
Barthe F, Bentellis I, Bernhard JC, Bensalah K, Champy C, Bruyere F, Olivier J, Audenet F, Parier B, Brenier M, Branger N, Lang H, Xylinas E, Boissier R, Rouget B, Chevallier D, Durand M, Ahallal Y. Barthe F, et al. Among authors: xylinas e. Fr J Urol. 2024 Oct 4;35(1):102753. doi: 10.1016/j.fjurol.2024.102753. Online ahead of print. Fr J Urol. 2024. PMID: 39369793 Free article.
364 results